tag:blogger.com,1999:blog-36634196.post7007852590258126419..comments2023-10-09T11:33:37.853-05:00Comments on The IN VIVO Blog: Effient and Onglyza Start Slow—And That May Not Be A Bad ThingChris Morrisonhttp://www.blogger.com/profile/04075266444951558159noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-36634196.post-6008902481720102282009-10-28T00:19:59.936-05:002009-10-28T00:19:59.936-05:00The market is completely different compared to whe...The market is completely different compared to when Prozac launched. Much different launch curve for a market shaping first of class therapy vs a second in class.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36634196.post-55155671060000817062009-10-27T11:19:06.314-05:002009-10-27T11:19:06.314-05:00Intersting topic and worth extensive coverage, BUT...Intersting topic and worth extensive coverage, BUT you should look closer at the launch of Prozac before describing it this way or using it as a good launch model.Anonymousnoreply@blogger.com